Previous close | 195.26 |
Open | 196.76 |
Bid | 0.00 x 0 |
Ask | 0.00 x 0 |
Day's range | 194.49 - 196.76 |
52-week range | 194.49 - 196.76 |
Volume | |
Avg. volume | N/A |
Market cap | 38.768B |
Beta (5Y monthly) | 1.39 |
PE ratio (TTM) | 92.62 |
EPS (TTM) | 2.10 |
Earnings date | 25 Apr 2023 - 01 May 2023 |
Forward dividend & yield | N/A (N/A) |
Ex-dividend date | N/A |
1y target est | N/A |
RESEARCH TRIANGLE PARK, N.C., March 14, 2023--In 2022, global clinical trial activity remained resilient even as the COVID-19 pandemic stretched through the year, with a 1% decline in non-COVID trial activity compared to 2021. COVID-19 trials as a percentage of total trial activity dropped from 10% to 6% of the 5,756 total trials run in 2022. Non-COVID trial activity increased by 8% between 2019 and 2022, suggesting a restoration to pre-pandemic growth rates, according to a new report, Global Tr
IQVIA Holdings Inc. ( NYSE:IQV ) shareholders might be concerned after seeing the share price drop 11% in the last...
RESEARCH TRIANGLE PARK, N.C., March 01, 2023--IQVIA Holdings Inc. ("IQVIA") (NYSE:IQV), announced today that Ron Bruehlman, executive vice president and chief financial officer, will speak at the Barclays Global Healthcare Conference in Miami, FL on Wednesday, March 15, 2023 at 9:30 a.m. ET.